{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-25-001617","form_type":"8-K","ticker":"ARTL","cik":"0001621221","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.498522+00:00","generated_at":"2026-05-17T08:32:04.444471+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artelo Biosciences reports positive interim Phase 2 data for ART27.13 in cancer cachexia; seeks licensing partner","bullets":["Interim Phase 2 CAReS: ART27.13 patients gained 6.38% mean body weight vs placebo loss of -5.42% at 12 weeks.","Lean body mass increased +4.23% in treatment group vs -3.15% loss in placebo at one month.","Safety: 22% of 32 patients had possibly related adverse events, all mild/moderate except one severe malaise; no drug-related serious AEs.","Company will not internally fund Phase 3; plans to pursue licensing/partnership for ART27.13 as most value-accretive path."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-25-001617","json":"https://secwatch.observer/filing/0001640334-25-001617.json","markdown":"https://secwatch.observer/filing/0001640334-25-001617.md","text":"https://secwatch.observer/filing/0001640334-25-001617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425001617/0001640334-25-001617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425001617/artl_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:32:04.444471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}